AstraZeneca’s Disposal of the Humira® Royalty Stream to Royalty Pharma
By Business Review Editor
Pharma Deals Review: Vol 2006 Issue 78 (Table of Contents)
Published: 6 Dec-2006
DOI: 10.3833/pdr.v2006.i78.420 ISSN: 1756-7874
Section: General
Fulltext:
Abstract
AstraZeneca sold the pre-existing royalty interest in Humira® (adalimumab), which AstraZeneca inherited along with the acquisition of Cambridge Antibody Technology (CAT) to Royalty Pharma...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS